Personalized vaccine trial offers new hope for Tough-to-Treat ovarian cancer

NCT ID NCT05920798

First seen Apr 06, 2026 · Last updated Apr 16, 2026 · Updated 2 times

Summary

This study is testing a new combination treatment for ovarian, fallopian tube, or primary peritoneal cancer that has come back after previous therapy. The treatment involves a personalized vaccine made from a patient's own immune cells, designed to teach the body to attack cancer, combined with an immunotherapy drug (pembrolizumab) that helps the immune system fight cancer. The main goals are to see if this combination is safe and if it can shrink tumors in up to 40 patients with recurrent disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT FALLOPIAN TUBE CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Mayo Clinic in Arizona

    RECRUITING

    Scottsdale, Arizona, 85259, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Mayo Clinic in Florida

    RECRUITING

    Jacksonville, Florida, 32224-9980, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Mayo Clinic in Rochester

    RECRUITING

    Rochester, Minnesota, 55905, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.